Summarized by Masters of Longevity from Longevity Technology.
A Tokyo lab is pursuing approval for PrecivityAD2 after US accuracy results.

Key Takeaways
- About 97.6% of positive PrecivityAD2 tests had brain amyloid.
- About 93.1% of negative PrecivityAD2 tests lacked brain amyloid.
- Study accuracy is based on diagnostic validation, not causal proof.



